Condition: Advanced Solid Tumors · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
This description comes directly from the study's public registry record.
Haiyan Hu · 0086-020-87343535 · xuri1104@163.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital，Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, He'nan, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, Hunan, China | Recruiting |
| The Central Hospital of Yongzhou | Yongzhou, Hunan, China | Recruiting |
| Liaoning Cancer Hospital & Institute | Shenzhen, Liaoning, China | Recruiting |
| Xijing Hospital | Xi’an, Shanxi, China | Recruiting |
| West China Hospital，Sichuan University | Chengdu, Sichuan, China | Recruiting |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| Zhejiang cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05944224